Shockingly, there are around 55,200 new breast cancer cases in the UK every year. As such, breast cancer is the most common invasive cancer in women and a leading cause of cancer death. In this exclusive interview, we speak with Richard Bahu, Chair of Trustees at the UK research charity Against Breast Cancer to hear about their vital work.

How did Against Breast Cancer come to fruition?

The total focus of Against Breast Cancer (ABC) is to stop secondary breast cancer from claiming lives. ABC was founded by Dr Anthony Leathem and his wife Patricia. At the time, Anthony was a pathologist at the Middlesex Hospital (later University College London) and his wife Patricia was a breast cancer theatre nurse at Oxford’s Churchill Hospital. They were deeply upset by the number of post-mortems he carried out each day on young women with breast cancer. They had to act by personally fundraising to support his research into breast cancer survival. This included Patricia planting their entire allotment with sweet peas to sell, and Anthony in his white coat outside Oxford Street tube station with a collection tin! Anthony’s research paper describing a difference between aggressive and non-aggressive breast cancer cells was the springboard for setting up ABC in 1993.

How does Against Breast Cancer support research? What types of research do you fund?

Our research strategy is set out in our Roadmap with three key areas: prevention, detection and new therapies. Prevention includes understanding how diet and lifestyle factors affect the risk of cancer recurrence. Detection aims to design better tools for the earlier detection of secondary cancer through biomarker discovery. New therapies aim to exploit the body’s immune system to create more effective treatments.

Our research strategy has created a significant critical mass of world-class researchers at Southampton University. We complement this with seed funding of researchers who have an exciting research idea but insufficient background research to apply for major funding. Often, these seed-funded projects enable them to successfully apply for major follow-on programmes. We are also committed to encouraging and developing young scientists in breast cancer research through a major fellowship programme at Oriel College, Oxford University.

How is the general public involved in your work?

We wouldn’t be where we are today without the involvement and support of the public. We have amazing supporters who help raise funds for our research projects. There are many ways people get involved, from taking part in local and national events, corporate giving, donating bras and clothes, volunteering their time and skills, and providing touching case studies. We are also grateful to those who leave a legacy in their wills. Some major companies and organisations choose ABC as their charity of the year and we work with them to give their staff a positive experience of our charity work. We also have research advocates who are people with experience with breast cancer and who provide valuable input into the types of projects that we fund.

One amazing and extremely moving example is that of Danielle. She was the focal point for a fundraising campaign in which a lock of her hair taken before her treatment was turned into diamond – the world’s most precious stone. At the end of the campaign, the diamond was incorporated into a necklace by a leading designer and donated to her young daughter.

We are, of course, in the midst of the COVID-19 pandemic. What specific difficulties has this brought to the work of Against Breast Cancer?

Clearly, this has had a dramatic effect not just on our fundraising but also on our staff and supporters. Being a smaller charity, we can react quickly to these challenges. Our team has risen to the challenge by being creative in moving activities online and into a virtual world. We have retained all our staff whilst other charities have sadly let many people go. This is a reflection of the lean management of the charity by an outstanding management team. We have also benefited from prudent management of our funds which has enabled us to cope robustly with the financial pressures.

There has been an impact on our research and with our full support, some of our researchers have joined the effort to combat the virus. However, we have been very pleased with how our researchers have sought to move their projects forward wherever possible. Again, we have continued to support all our funded projects and do not envisage cutting back any of them.

What would you say are Against Breast Cancer’s biggest achievements to date?

Reaching our 25th anniversary in 2018 was a big milestone for the charity. We are particularly proud of achieving our Biobank which is a collection of samples and lifestyle data collected from over 3,000 women over a period of 5 years post-cancer diagnosis. This is such a valuable research resource and one of the largest of its kind in the UK. To date, our research funding has now exceeded £7m and we have laboratories located at one of the world’s leading centres researching secondary breast cancer. ABC’s committed funding up to 2028 sees a portfolio of £4.5m with further funding envisaged for seed grants.

Looking now to the future, what are the main challenges and goals for Against Breast Cancer over the next 5–10 years?

ABC is now on a clear path to have a major impact on secondary breast cancer deaths over the next 5–10 years. The biggest challenge is managing the expectations of our supporters as they obviously want quick results whereas the complexity of the research requires a steady and sustained long-term effort to which we are committed. This means we have to provide clear and truthful communication about our research as often people see articles in the press and on social media which talk about breakthroughs but which often are still some way from being implemented in clinical practice.

W: https://www.againstbreastcancer.org.uk/

Twitter: @againstbc

Reference
https://doi.org/10.33548/SCIENTIA642

Want to republish our articles?

 

We encourage all formats of sharing and republishing of our articles. Whether you want to host on your website, publication or blog, we welcome this. Find out more

Creative Commons Licence
(CC BY 4.0)

This work is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

What does this mean?

Share: You can copy and redistribute the material in any medium or format

Adapt: You can change, and build upon the material for any purpose, even commercially.

Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.


More articles you may like

Professor Michael Ryan | What the Ugandan Response to HIV/AIDS Can Teach Us About Collaborative Governance

Professor Michael Ryan | What the Ugandan Response to HIV/AIDS Can Teach Us About Collaborative Governance

Persistent problems such as poverty, disease and hunger are of critical interest to organisation and management scholars. Developing countries often struggle with intractable social issues, including susceptibility to epidemics. The complexity of these challenges means it can be difficult for leaders to organise governance and ensure that resources and capabilities are effectively coordinated. Professor Michael Ryan looks at the case study of the HIV/AIDS response in Uganda, and asks how this can contribute to our understanding of public organisation and state capacity. In particular, he explores how Uganda was successful in using collaborative governance to manage the HIV/AIDS crisis.

Professor Aaron Brown | Brown Adipose Tissue and Optogenetics – The Next Step in Obesity Treatment?

Professor Aaron Brown | Brown Adipose Tissue and Optogenetics – The Next Step in Obesity Treatment?

Adipose tissue is more commonly known as body fat. Unlike white adipose tissue, which is linked to negative cardiovascular outcomes such as metabolic syndrome, brown adipose tissue is positively related to health and may reduce the risk of cardiometabolic diseases. Professor Aaron Brown and his team at the MaineHealth Institute for Research are working to understand brown adipose tissue regulation and explore its therapeutic potential. They have already made significant advancements through the application of optogenetics, a cutting-edge technique that harnesses the power of light to precisely manipulate specific cellular processes.

Dr Kimberly Kay Hoang | Who Gets to Be a Theorist? The Oppression of Marginal Theories

Dr Kimberly Kay Hoang | Who Gets to Be a Theorist? The Oppression of Marginal Theories

Who gets to be a theorist? What kinds of theoretical work get marginalised in academic research? And how does this oppression play out in the peer-review process? Dr Kimberly Kay Hoang is a Professor of Sociology at the University of Chicago. She has explored how difficult it is to get your sociology research published if you are not using research deemed to be legitimate by reviewers. She brings awareness to these issues and argues for change amongst scholars so that new forms of knowledge are not missed, especially regarding feminist, minority and racial theories.

Dr Kimberly Kay Hoang | Spiderweb Capitalism: The Secret Financial Webs Built by the Ultra-Wealthy

Dr Kimberly Kay Hoang | Spiderweb Capitalism: The Secret Financial Webs Built by the Ultra-Wealthy

The anonymous leak of the Panama Papers in 2016 revealed how the exceptionally wealthy (such as politicians, celebrities and business leaders) hide their money and exploit secretive offshore tax regimes. Dr Kimberly Kay Hoang is a Professor of Sociology at the University of Chicago, and after six years of research, hundreds of interviews and travelling 350,000 miles, she published Spiderweb Capitalism: How Global Elites Exploit Frontier Markets. She uncovered the mechanisms behind the movement of money into and out of Southeast Asia, and how that money travels all over the world.